Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Carcinoma, Non-Small-Cell Lung 57Breast Neoplasms 35Neoplasms 32Parkinson Disease 4, Autosomal Dominant Lewy Body 25Multiple Myeloma 24Leukemia, Myeloid, Acute 20Recurrence 18Neoplasm Metastasis 17Colorectal Neoplasms 17Ovarian Neoplasms 15Lymphoma, Non-Hodgkin 15Melanoma 14Leukemia, Lymphocytic, Chronic, B-Cell 14Carcinoma, Renal Cell 14Leukemia 13Lymphoma, Follicular 12Urinary Bladder Neoplasms 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Myelodysplastic Syndromes 11Lung Neoplasms 11Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Hematologic Neoplasms 10Carcinoma, Hepatocellular 10Stomach Neoplasms 9Prostatic Neoplasms 9Lymphoma, Mantle-Cell 9Lymphoma, Large B-Cell, Diffuse 9Lymphoma 9Adenocarcinoma 9Thyroid Neoplasms 8

Interventions

blinatumomab 2pegaspargase 1asparaginase erwinia chrysanthemi recombinant 1Methotrexate 1Ifosfamide 1Dexamethasone 1Daunorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Has announcements × Lymphoproliferative Disorders × Clear all
NCT02393859 2024-05-29

Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)

Amgen

Phase 3 Completed
111 enrolled 23 charts 1 FDA
LymphoidOther hematologic neoplasm

Immunoproliferative Disorders, Lymphoproliferative Disorders, Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01207388 2020-02-10

BLAST

Amgen Research (Munich) GmbH

Phase 2 Completed
116 enrolled 23 charts 1 FDA
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Lymphatic Diseases, Lymphoproliferative Disorders, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡